Unknown

Dataset Information

0

Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis.


ABSTRACT: Objectives:To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson's disease (PD). Methods:Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included. Effect sizes (Cohen's d), the standardized mean difference in the scores of each cognitive domain, were compared using a random-effects model (MetaXL version 5.3). Results:Three studies were included in the final analysis. For a change in complex attention in PD with mild cognitive impairment (MCI), the estimated effect size was small and nonsignificant (0.16 (95% CI: -0.09, 0.42), n?=?42). For changes in executive function, perceptual-motor function, language, social cognition, and learning and memory, the estimated effect sizes were small and medium, but nonsignificant. A deteriorative trend in executive function was observed after atomoxetine treatment in PD with MCI. For a change in global cognitive function in PD without MCI, the estimated effect size was large and significant. Conclusion:In idiopathic PD with MCI, atomoxetine does not improve complex attention. Also, a deteriorative trend in the executive function was noted.

SUBMITTER: Ghosh A 

PROVIDER: S-EPMC7049416 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis.

Ghosh Abhinaba A   Das Saibal S   Behera Sapan Kumar SK   Ramakrishnan Kirubakaran K   Selvarajan Sandhiya S   Kandasamy Preeti P   Nair N Sreekumaran NS  

Parkinson's disease 20200217


<h4>Objectives</h4>To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson's disease (PD).<h4>Methods</h4>Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included. Effect sizes (Cohen's <i>d</i>), the standardized mean difference in the s  ...[more]

Similar Datasets

| S-EPMC8455525 | biostudies-literature
| S-EPMC6869398 | biostudies-literature
| S-EPMC4065022 | biostudies-literature
| S-EPMC4384955 | biostudies-literature
| S-EPMC6261669 | biostudies-literature
| S-EPMC4856878 | biostudies-literature
| S-EPMC4958901 | biostudies-literature
2015-12-01 | GSE51923 | GEO
| S-EPMC6953353 | biostudies-literature
| S-EPMC8615553 | biostudies-literature